Serum angiotensin-converting enzyme in multiple sclerosis

Arch Neurol. 1997 Aug;54(8):1012-5. doi: 10.1001/archneur.1997.00550200068012.

Abstract

Objective: To determine the extent and significance of serum angiotensin-converting enzyme (ACE) elevation in multiple sclerosis (MS) and the correlation between serum ACE activity and clinical and magnetic resonance imaging (MRI) indicators of disease activity.

Design: A retrospective cross-sectional study of 45 consecutive patients with clinically definite MS and a longitudinal study of 30 additional patients with clinically definite MS involved in a long-term study of neurologic function and MRI in MS.

Setting: Comprehensive MS center of a tertiary care university hospital.

Subjects: A total of 75 patients with clinically definite MS and 31 healthy controls.

Methods: Serum ACE activity was measured using a spectrophotometric assay and correlated with clinical indicators of disease activity and with total cerebral MS lesion volume measured by MRI.

Results: An elevated ACE activity was found in 17 (23%) of 75 patients with MS as compared with 2 (6%) of 31 healthy controls. Changes in serum ACE activity correlated with changes in total plaque volume on MRI.

Conclusions: Serum ACE activity may be an indicator of disease activity in longitudinal analysis. Also, elevated ACE activity in a patient with otherwise typical MS need not raise suspicions of alternative diagnoses.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Female
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Multiple Sclerosis / blood*
  • Multiple Sclerosis / enzymology*
  • Peptidyl-Dipeptidase A / blood*
  • Retrospective Studies

Substances

  • Peptidyl-Dipeptidase A